All PlansCoverageMedium impact
Recall: Atovaquone
UPMC Health Plan·Infectious Disease, Pulmonology, Pediatrics +2 more·Pharmacy
Effective date
Apr 2, 2023
We identified it
Aug 7, 2026
Summary
Camber Pharmaceuticals is recalling Atovaquone Oral Suspension 750 mg/5 mL lot #E220182 (expiration 12/2023) due to possible bacterial contamination. This medication is used for PCP prevention and treatment in patients who cannot tolerate standard therapies. The billing team must identify and flag claims for this specific lot to prevent billing for a recalled product.
Action Required
Immediately: Billing and clinical teams must identify all claims submitted for Atovaquone Oral Suspension 750 mg/5 mL lot #E220182 with expiration date 12/2023. Flag these claims in the billing system and do not process reimbursement until replacement medication is verified. Notify prescribing providers and pharmacy to stop dispensing this lot. Contact affected patients to ensure they received alternative medication (trimethoprim-sulfamethoxazole or other approved alternatives). Document all affected claims for compliance audit. Failure to halt billing on this contaminated lot may result in claim denials, regulatory penalties, and patient safety liability.